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Abstract
Background: More than half of persons living with HIV (PLWH) in the United States are insufficiently engaged in
HIV primary care and not taking antiretroviral therapy (ART), mainly African Americans/Blacks and Hispanics. In the
proposed project, a potent and innovative research methodology, the multiphase optimization strategy (MOST),
will be employed to develop a highly efficacious, efficient, scalable, and cost-effective intervention to increase
engagement along the HIV care continuum. Whereas randomized controlled trials are valuable for evaluating
the efficacy of multi-component interventions as a package, they are not designed to evaluate which specific
components contribute to efficacy. MOST, a pioneering, engineering-inspired framework, addresses this problem
through highly efficient randomized experimentation to assess the performance of individual intervention
components and their interactions. We propose to use MOST to engineer an intervention to increase engagement
along the HIV care continuum for African American/Black and Hispanic PLWH not well engaged in care and not
taking ART. Further, the intervention will be optimized for cost-effectiveness. A similar set of multi-level factors
impede both HIV care and ART initiation for African American/Black and Hispanic PLWH, primary among them
individual- (e.g., substance use, distrust, fear), social- (e.g., stigma), and structural-level barriers (e.g., difficulties
accessing ancillary services). Guided by a multi-level social cognitive theory, and using the motivational interviewing
approach, the study will evaluate five distinct culturally based intervention components (i.e., counseling sessions,
pre-adherence preparation, support groups, peer mentorship, and patient navigation), each designed to address a
specific barrier to HIV care and ART initiation. These components are well-grounded in the empirical literature and
were found acceptable, feasible, and promising with respect to efficacy in a preliminary study.
Methods/design: Study aims are: 1) using a highly efficient fractional factorial experimental design, identify which
of five intervention components contribute meaningfully to improvement in HIV viral suppression, and secondary
outcomes of ART adherence and engagement in HIV primary care; 2) identify mediators and moderators of
intervention component efficacy; and 3) using a mathematical modeling approach, build the most cost-effective
and efficient intervention package from the efficacious components. A heterogeneous sample of African American/
Black and Hispanic PLWH (with respect to age, substance use, and sexual minority status) will be recruited with a
proven hybrid sampling method using targeted sampling in community settings and peer recruitment (N = 512).
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Discussion: This is the first study to apply the MOST framework in the field of HIV prevention and treatment. This
innovative study will produce a culturally based HIV care continuum intervention for the nation’s most vulnerable
PLWH, optimized for cost-effectiveness, and with exceptional levels of efficacy, efficiency, and scalability.
Trial registration: ClinicalTrials.gov, NCT02801747, Registered June 8, 2016.
Keywords: HIV care continuum, Antiretroviral initiation, HIV care, Multiphase optimization strategy, MOST, African
American, Black, Hispanic, Disparities, Intervention
Background
Even with recent important advances in the efficacy and
tolerability of HIV treatment [1–6], serious gaps persist
in the HIV care continuum in the United States [7, 8].
The Centers for Disease Control and Prevention esti-
mates that of 1.2 million Americans living with HIV,
60% are not retained in HIV care; 63% are not taking
antiretroviral therapy (ART); and 70% have detectable
HIV viral load (VL) [9]. Poor engagement along the HIV
care continuum increases risk for morbidity and early
mortality [10–12], hospitalizations and increased health
care costs [13, 14], and risk of forward transmission of
HIV. Indeed, poor retention in HIV primary care is a
principal cause of HIV/AIDS-related mortality [15–18],
and lack of ART initiation further places persons living
with HIV (PLWH) at elevated risk for substandard CD4
and VL outcomes [11, 19, 20].
Because most PLWH are African American/Black or
Hispanic [21], gaps in engagement along the HIV care
continuum are concentrated among these populations.
Moreover, compared to their White peers, African
American/Black and Hispanic PLWH (AABH-PLWH)
are more likely to be diagnosed late in the course of
their HIV disease, delay uptake of ART, discontinue
ART, and to have higher rates of morbidity and earlier
mortality from HIV [22–25]. Further, these racial/ethnic
disparities are found among all major risk categories;
namely, persons who inject drugs (PWID), men who
have sex with men (MSM), and heterosexuals [26, 27].
The Centers for Disease Control and Prevention, Office
of AIDS Research [28], and National HIV/AIDS Strategy
[29] have stressed the importance of eliminating racial/
ethnic disparities in HIV health outcomes, thereby sig-
naling the need for culturally based HIV care continuum
interventions [29–31].
The MOST framework
The primary goal of the present study is to use the
innovative multiphase optimization strategy (MOST) to
select individual intervention components to comprise
an optimized behavioral intervention, where the optimized
intervention is the one that provides the greatest improve-
ment in health outcomes achievable within the specified
resource constraints [32]. MOST is an engineering-
inspired framework and systematic method for identifying
the optimized combination of intervention components
before testing an intervention in a resource-intensive ran-
domized controlled trial (RCT). MOST consists of three
stages: 1) preparation, 2) optimization, and 3) evaluation
of the optimized intervention in an RCT [32]. While the
RCT is an excellent approach for evaluation of an inter-
vention package as a whole, it was never intended to pro-
vide information about the performance of the individual
components making up the intervention package. By
contrast, MOST calls for empirically examining the effi-
cacy of each separate intervention component, along with
its resource requirements and costs.
Objectives of the present study
In the present study, the goal is to select the set of interven-
tion components likely to improve health outcomes to the
greatest extent per dollar spent, yielding a cost-effective, ef-
ficient, and scalable culturally based behavioral intervention
for AABH-PLWH. In recent preliminary research, we iden-
tified a set of promising intervention components for
AABH-PLWH not taking ART and poorly engaged in HIV
care [33, 34]. In the present study, an innovative and
economical fractional factorial experimental design will be
used to examine the effects of a set of five individual
intervention components, their interactions, as well as
mediation and moderation effects for each individual inter-
vention component, providing a detailed look at the mecha-
nisms by which each component works. Then, in the
optimization process, based on modeling analyses, we will
identify the combination of intervention components (likely
2–3 components) with the greatest levels of efficacy and
cost-effectiveness, eliminating poorly performing, costly, or
ineffective components. This new combination of compo-
nents is called the “optimized intervention” [35–37]. The
optimized intervention developed using this powerful new
approach has the potential to make a major impact on en-
gagement in HIV care and uptake of ART among AABH-
PLWH, improving the health of this population, reducing
forward transmission of HIV, and decreasing racial/ethnic
HIV disparities – all national priorities [28, 29, 38, 39]. This
project will be the first application of the MOST framework
in the field of HIV prevention and treatment, and will result
in the first optimized intervention aimed at improving
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engagement along the HIV continuum of care using bio-
logical outcomes (namely, CD4 and VL levels).
Aims of the study
Thus the aims of the present study are:
Aim 1: Using a highly efficient experimental design,
identify which of five intervention components contrib-
ute meaningfully to improvement in the primary out-
come, HIV viral suppression, and secondary outcomes,
absolute HIV viral load, ART adherence, and engage-
ment in HIV primary care, all assessed via objective bio-
markers or through the medical record.
Aim 2: Identify mediators and moderators of the effi-
cacy of each intervention component (e.g., substance use
history, sexual minority status), and also of interaction
effects between components.
Aim 3: Using a mathematical modeling approach, build
the most cost-effective and efficient intervention package
from the components found to be efficacious in Aim 1.
Methods/design
Overview of the study
The present study focuses on African American/Black
and Hispanic PLWH not well engaged in HIV care nor
taking ART, referred to as “PLWH-NECTA”. We will en-
roll a heterogeneous sample of PLWH-NECTA (with re-
spect to age, substance use, mental health, and sexual
minority status). PLWH-NECTA are not typically found
in HIV clinics. Instead, participants (N = 512) will be
recruited with a proven hybrid sampling method using
targeted sampling and peer recruitment, described below
[33]. The present study is comprised of three stages: (1)
Refinement (6 months); (2) Implementation, Cost Effect-
iveness Analysis, and Optimization (48 months); and (3)
Final (6 months). Intervention optimization in stage 2
will proceed as follows: Five promising individual inter-
vention components, grounded in an integrated social-
cognitive theory (the theory of triadic influence com-
bined with self-determination theory), will be examined
by means of a fractional factorial experiment. The five
intervention components, each of which is guided by the
motivational interviewing counseling approach, and
described in detail below, are: (A) Motivational Interview-
ing (MI) individual counseling sessions; (B) Pre-adherence
preparation; (C) Peer mentorship; (D) Focused support
groups; and (E) Navigation. Each component addresses
one theoretical mediator or one small set of theoretical
mediator(s) linked to known barriers to good engagement
in HIV care and ART uptake among PLWH-NECTA, as
shown in the study’s conceptual model (Fig. 1), and
described below. All participants will receive a Core inter-
vention session and be randomly assigned to one of 16
experimental conditions. Time and cost expenditure data
for each intervention component will be collected. Then,
mathematical modeling based on the results of the
experiment will determine the most efficacious and cost-
effective combination of intervention components, elimin-
ating ineffective components.
Fig. 1 Conceptual model grounded in the theory of triadic influence and self determination theory
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Theoretical model
The present study is guided by a theoretical model incorp-
orating the theory of triadic influence [40] and self deter-
mination theory [41, 42]. The theory of triadic influence is
a multi-level social-cognitive theory articulating three
“streams of influence” acting simultaneously on health
behavior; namely, the individual, social, and structural.
Complementing the theory of triadic influence, self deter-
mination theory highlights the importance of durable,
high-quality, intrinsic motivation for behavior change
[41, 42]. The integrated theoretical model assumes the
lack of HIV care and ART initiation are not independent:
those who fear or otherwise decline ART present less fre-
quently for HIV care [43, 44], and those not well engaged
in HIV care rarely gain access to ART [21]. Importantly,
these two gaps in the HIV care continuum – poor engage-
ment in HIV care and low uptake of ART - are largely
driven by the same set of multi-level risk factors and bar-
riers [33, 34]. Guided by this integrated theoretical model,
we next describe the primary barriers AABH-PLWH ex-
perience to both HIV care and ART initiation with sus-
tained good adherence [45–47].
Description of barriers to HIV care and ART
At the individual level of influence primary barriers to HIV
care/ART for AABH-PLWH include negative health beliefs
such as medical distrust, negative outcome expectancies,
low levels of “readiness” [48–52], and negative emotions
about care/ART, including fear [53–55]. Indeed, the pri-
macy of fear as a barrier; namely, fear of being pressured to
take ART in health care settings, of ART’s side effects and
toxicities, and possible negative effects on relationships if
on ART, cannot be over-stated [56, 57]. Substance use is
another common barrier [33, 58–61], as are mental health
concerns, primarily depression [62–65]. Further, lack of
knowledge about care/ART guidelines [48, 66, 67] impedes
ART/care, and PLWH often decline ART because they lack
behavioral skills to maintain adherence to ART [68, 69].
Barriers at the social level of influence include a lack of
positive “successful” peer role models who are regularly
engaged in HIV care and taking ART with good
adherence, who can challenge prevalent social/peer norms
that health care systems cannot be trusted and ART is
toxic and should be avoided [43, 44, 46]. Social isolation
and low levels of social support also impede HIV care and
ART use [70, 71], as does HIV stigma, compounded by
stigma associated with poverty, substance use, and/or sex-
ual minority status [72–74].
At the structural level of influence, barriers include chal-
lenges negotiating the health care system, including rela-
tions with providers [75, 76], transportation problems, and
access to care for substance use and mental health con-
cerns, as well as HIV [44, 48, 77]. Interventions may not
eliminate structural barriers, but can reduce their effects
by increasing participants’ options [78]. Barriers at all three
levels are commonly rooted in poverty [44, 77, 79, 80] and
combine synergistically to reduce AABH-PLWH’s motiv-
ation, behavioral skills, and access to HIV care and ART.
On the other hand, factors facilitating good health out-
comes operate concurrently with barriers, including intrin-
sic motivation to achieve good health [44, 81–84] and
supportive network members [85]. As shown in Fig. 1,
and described in more detail below, the present study will
test a set of intervention components designed to address
the primary barriers AABH-PLWH experience to HIV
care and ART initiation at these three levels of influence.
The present study attends to the needs of MSM
African American/Black and Hispanic MSM are greatly
over-represented among the population of PLWH, making
up more than half of the population of PLWH nationally
[86]. Similar to other subgroups of AABH-PLWH, African
American/Black and Hispanic MSM have suboptimal rates
of linkage to care, retention in care, ART initiation, and
HIV viral suppression [30]. Prior epidemiologic research
highlights a number of clinical and socio-structural factors
that create barriers to engagement along the HIV care
continuum for African American/Black and Hispanic
MSM. These include stigma related to HIV, as well as to
sexual minority status, substance use, stress, and depression
[72, 87–90]. The present study includes a focus on this crit-
ical subpopulation of PLWH. We estimate 55–60% of
males in the present study will be MSM [33, 34].
The present study addresses substance use and mental
health concerns
Drug and alcohol use, and substance use problems, are
endemic among PLWH [59, 60] and serve as major
barriers to engagement along the HIV care continuum
[59–61, 91, 92]. Cocaine, marijuana, opioids, and alcohol
are the most frequently used substances, and poly-
substance use is common [59, 92]. While recent injection
drug use is not highly prevalent in this population (<4%)
[60, 92], lifetime injection drug use prevalence is sub-
stantial (~17%) and associated with poor HIV outcomes
[62], including delayed HIV diagnosis, reduced entry
into and retention in HIV care, delayed initiation of
ART, inferior adherence to ART [93, 94], and poor
treatment outcomes [59]. Yet substance use does not
preclude engagement in HIV care and good ART adher-
ence [95], and substance use problems, while they may
be serious, are addressable. Among PWID, opioid substi-
tution therapy is associated with better adherence to
ART [95–98], and a number of promising behavioral
interventions have been developed for substance users
living with HIV [97, 99–101]. Given the critical role sub-
stance use plays in HIV disparities, intervention efforts
for HIV-infected substance users are vital [102]. Based
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on our own research [33, 74] and on national data [92],
we estimate 55% of participants in the present study will
be current substance users, primarily non-injectors, 25%
will be past users (including PWID), and 20% will be
non-users. Relatedly, mental health problems are wide-
spread among AABH-PLWH, mainly depression and
anxiety. We estimate 60–65% of the sample in the
present study will evidence mental health distress at
clinically significant levels [33, 34].
Explanation for the choice of intervention components to
be tested
The intervention components to be evaluated in the
present study were developed and tested as a packaged
intervention in a previous intervention development
RCT. The intervention, called “Heart to Heart” (HTH),
was highly efficacious, producing substantial reductions
in VL, the study’s primary outcome, assessed via the
medical record. Further, the intervention was highly
acceptable and feasible, including for substance users,
sexual minorities, and both males and females, and re-
tention was excellent (> 95% attended the intervention;
90% completed a 4-month follow up assessment and
80% complete the 8-month follow up assessment) [34].
Rates of ART initiation were similar across arms (~ 58%)
but 8 months post-baseline, participants in the interven-
tion arm were three times more likely to evidence “good”
(that is, 7 day/week) adherence (60% vs. 26.7%; p = 0.087;
OR = 3.95), as assessed via ART concentrations in hair
samples [103], and had significantly lower VL (interven-
tion log10 VL = 1.63 [SD = 0.67], controls 2.51 [SD = 1.55],
OR = 3.70; p = 0.02) than controls based on medical
records.
Findings from the HTH study as well as the larger
empirical literature on interventions for PLWH formed
the basis for the selection of individual intervention
components to be tested in the present study. We used
the following guidelines for selecting components. Each
component must: address one or one small set of theor-
etical mediator(s); be distinct from the others in content,
length, delivery method, and/or approach; have, at mini-
mum, preliminary evidence of efficacy or promise in the
empirical literature; have been found feasible for and ac-
ceptable to the population under study; not require that
any other component be administered along with it in
order to be efficacious; and be guided by a detailed man-
ual. We formed an Intervention Working Group, led by
Dr. Gwadz, the PI of the HTH study and Co-PI of the
present study (with Dr. Linda Collins). The Intervention
Working Group was made up of senior research scien-
tists expert in AABH-PLWH, members of the target
population, and experienced clinical interventionists,
who applied these criteria in an iterative process using
Intervention Mapping, to select the most promising
components.
Description of intervention components to be tested
The Intervention Working Group identified five discrete
intervention components for inclusion, as well as a pre-
paratory Core intervention session to be conducted with
all participants. Each component has two “levels” to be
compared in the fractional factorial design: either yes/pro-
vided vs. no/not provided (Components A-D), or short
version vs. long version (Component E). The five compo-
nents selected for study are described below. The present
study will be a definitive test of the efficacy of each com-
ponent selected. Components will be guided by detailed
manuals and will be culturally appropriate. Further, com-
ponents will be individually tailored on substance use,
mental health problems, and sexual minority status; man-
ualized “algorithms” will be used to query or provide feed-
back (from baseline data) on these indices, followed by a
series of prompts to guide the individually tailoring.
Core intervention session (~60 min)
All participants will receive a foundational Core inter-
vention session. The goals of this component are to: 1)
foster engagement and build trust/relationships and 2)
provide standard treatment education on the current
U.S. Department of Health and Human Services recom-
mendations for frequency of HIV care appointments and
timing of ART initiation [104, 105]. The primary theor-
etical target is HIV treatment knowledge.
Component A: MI counseling sessions, ~60–90 min each,
4 sessions
Sessions will be conducted with participants individually
and made up of discrete exercises. Each session will in-
clude 1–2 culturally based video narrative segments to
highlight key issues and foster discussion [106, 107]. Ses-
sion 1 addresses barriers to HIV care. Sessions 2 and 3
target barriers to ART (S2: evoking barriers, fostering
readiness; S3: decisions, plans). Session 4 addresses ad-
herence, individual barriers and their solutions in depth,
and finalizing care/ART plans. This component’s pri-
mary theoretical targets are health beliefs (e.g., outcome
expectancies, self-efficacy, medical distrust), and emo-
tions (e.g., concerns/fears of ART).
Component B: Pre-adherence preparation (2–6 wk. period)
The Health Resources and Services Administration
(HRSA) provides guidelines for preparing PLWH-
NECTA for treatment success [108–110], an approach
supported by the research literature [69, 105, 110–112].
Component B is grounded in the HRSA guidelines. Its
goals are to prepare the physical and social “adherence
environment,” put long-term ART supports in place, and
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build adherence skills. Component B is flexible and indi-
vidualized and will first entail an in-person orientation
home session (< 90 min) to assess readiness for ART,
identify individual barriers to adherence prior to initiating
ART (e.g., substance use), link adherence to daily activities
to build habits, put educational and visual aids and re-
minders in place, understand side effects, identify and in-
volve long-term supports/supporters who can reinforce
successes, and plans to minimize lapses if doses are
missed. With the participant’s consent, the health care
provider will be queried regarding the simplest dosing
schedule [108, 113]. Next, a series of trial runs, with feed-
back, will be conducted (1–4 week-long trials). Trial runs
will comprise 1-week practice trials with a daily pill regi-
men similar to the actual future ART regimen (obtained
from providers, if possible) but using vitamins. Adherence
to vitamins will be monitored with medication event mon-
itoring system (MEMS) caps or a similar electronic adher-
ence monitoring device, to help participants work toward
a goal of >85% adherence [114]. After each week-long
trial, participants will receive feedback from the study
interventionist on their adherence patterns, a key strategy
to boost motivation [84], and barriers of/facilitators to
adherence, if any, will be explored. Participants will make
a personal decision about ART initiation with their pro-
viders; those with <85% adherence will not be discouraged
initiating ART. This component’s primary theoretical tar-
get is behavioral skill to manage ART adherence.
Component C: Peer mentorship (regular interactions with a
highly trained “successful” peer mentor [4 months])
Linking PLWH with peer mentors is an efficacious
approach to HIV-related behavior change [15, 115–121].
Successful peer mentors (i.e., demographically similar
PLWH who have consistently engaged in care and are
taking ART with good adherence) can serve as credible
role models and challenge negative peer norms about
HIV care and ART [15, 115, 118]. The training curricu-
lum for and core elements of Component C are based
on the HRSA-funded Peer Education & Evaluation Re-
source (PEER) model [122]. Meeting approximately
weekly face-to-face or by phone, the role of the peer
mentor will be to: provide informal counseling; model
healthy HIV behavior; provide practical tips for man-
aging care/ART based on his/her personal experience;
and provide resources to address barriers to care/ART
[122, 123]. This component’s primary theoretical targets
are peer modeling and peer norms. Secondary theoret-
ical targets are social support and stigma.
Component D: Focused support groups (6 groups, ~90 mins.
Each, every 2–3 weeks over 4 months)
Support groups can address the social isolation and stigma
endemic among PLWH-NECTA [124–131]. Component
D aims to provide emotional and instrumental support,
reduce stigma, give acceptance or validation, and encour-
age shifts in perspective [132, 133]. Groups will be guided
by the MI approach, facilitated by a skilled interventionist,
focus on barriers to and decisions regarding care/ART,
provide general social support, and attend to issues MSM,
substance users, and those with mental health concerns
face [134]. This component’s primary theoretical targets
are social support and stigma regarding care/ART status.
This is the only intervention component where partici-
pants from the different experimental conditions will
engage with each other, raising the possibility of contam-
ination among participants. A description of possible types
of contamination and procedures to prevent contamin-
ation are described below.
Component E: Navigation (3 months [short] vs. 6 months
[long])
Navigation is an efficacious, flexible, individualized,
strengths-based approach to assist PLWH in identifying
and overcoming barriers to health services [135–139].
Participants will be randomized to receive a short
(3 months) or long (6 months) period of navigation [34,
140]. All participants receive at least the short version of
this component because of the primacy of structural
barriers to HIV care and ART, and need for ancillary
services among PLWH-NECTA (e.g., for substance use
and mental health), although the optimal duration of
navigation is not known [136, 140]. Component E is
based on the HRSA HIV System Navigation model
[136]; delivered by a trained interventionist; menu-
based; and highly focused. Core elements include: an
initial face-to-face meeting (< 90 mins.) for review of
participant’s readiness for and barriers to care/ART, in-
cluding substance use and mental health, and creation of
a Change Plan/Action Plan, and a minimum of weekly
phone (including text messages), email, and in-person
meetings during the navigation period, depending on
need. The menu of activities includes: screening and
“Fast Track” referrals for substance use, mental health,
and other problems including MSM-friendly sites;
communication with primary care provider, as needed,
about the participant’s service needs and care/ART
plans; and accompaniment to health care appointments.
This component’s primary theoretical target is ameliorat-
ing structural barriers to care and ART.
Outcomes
Study outcomes will be assessed using objective data.
The primary outcome is HIV virologic suppression
analyzed as a dichotomous measure (assessed via lab
report). Secondary outcomes include 1) absolute HIV
VL (a continuous measure, assessed via lab report), 2)
adherence to ART as assessed by ART concentrations in
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hair samples [103], and 3) engagement in HIV primary
care, defined below (assessed via medical records) [105].
Study setting
The study will be located in New York City, which
has a large HIV epidemic, with approximately 115,000
PLWH, >75% African American/Black and Hispanic
and ~55% MSM. Comparable to other urban areas,
New York City has a large network of HIV care set-
tings and all PLWH have access to care and ART
[141]. Nonetheless, at the time the study was planned,
New York City data indicated 45% were not retained
in care, 49% were not taking ART, and 59% were not
virally suppressed [142]. Thus >50,000 PLWH-NECTA
reside in the local area, overwhelmingly African American/
Black and Hispanic, concentrated in geographic areas with
elevated rates of poverty [141, 143]. We will locate a
project field site in one of the geographical areas with
high rates of poverty and prevalent HIV (e.g., in
central Brooklyn) and project activities will take place
there.
Trial design
The effects of the five individual components will be
examined by means of an innovative, highly efficient
fractional factorial experiment. A factorial experiment is
an efficient way to examine these five components, for
two reasons. First, factorial experiments separate com-
ponent effects, enabling estimation of the main effect
contribution of each candidate component and interac-
tions between components. Second, factorial experi-
ments can be economical compared to alternative
designs, because they often require substantially fewer
participants to achieve the same statistical power for
component effects [36, 144].
As noted above, we plan to conduct a fractional factorial
experiment involving five factors, each with two levels.
The first four factors are: (A) MI counseling sessions; (B)
Pre-adherence preparation; (C) Peer mentorship; and (D)
Focused support groups. For components A-D, the levels
of each of these factors are “no” (not included in the
intervention) and “yes” (included in the intervention). The
levels of the fifth factor, (E) Navigation, are “short
duration” navigation (3 months) and “long duration” navi-
gation (6 months).
Our power analysis, presented below, indicates that
N = 512 is sufficient to maintain power of at least 0.8.
Conducting five individual experiments, one for each
component, would require N = 2560, or five times as
many participants as the factorial experiment, and com-
parative, dismantling, and constructive experimental de-
signs would require N = 1536, or three times as many
participants [36]. The fractional factorial design selected
for this study requires 16 experimental conditions. The
16 conditions in the design selected for the present
study are presented in Fig. 2, and procedures used to se-
lect these conditions are described below.
This design should not be considered a 16-arm RCT.
The purpose and logical underpinnings of the factorial
experiment, as well as the logic behind powering factor-
ial experiments, are different from those of an RCT. The
purpose of an RCT is direct comparison of the efficacy
or effectiveness of two or more versions of an interven-
tion. By contrast, although each of the 16 conditions in
Fig. 2 represents a viable version of the enhanced HTH
intervention, a factorial design never calls for direct
comparison of these experimental conditions to see
which one is best. Instead, the purpose of a factorial ex-
periment in this context is to identify which components
are (a) efficacious and/or (b) augment the efficacy of
other components, so that we can select the ones that
form the most cost-effective intervention. Efficiency
comes from basing estimates of all estimated main ef-
fects and interactions on all 16 conditions in the factor-
ial experiment. For example, the main effect of MI
counseling sessions will be estimated by comparing the
mean outcome across Conditions 1–8 vs. the mean
outcome across Conditions 9–16. All participants are in-
cluded in the estimate of each main effect. This is quite
different from how RCTs are analyzed, and is why
Fig. 2 Conditions in the fractional factorial design
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factorial experiments can have a relatively small per-
condition sample size and still have excellent power if
the total N is sufficient [36, 144]. The fractional factorial
design does not contain a traditional control group; it
does not require one, because individual conditions are
never compared [36]. Instead, each factor has two levels,
one of which serves as a control for that factor.
Other advantages of the factorial experiment include
that cost-effectiveness can supplement efficacy as criteria
for determining which components will be included in
the final optimized intervention, thereby increasing the
pre-test likelihood that the MOST-engineered interven-
tion is cost-effective. If a component is efficacious but
with a much higher cost than other components with
comparable efficacy, the high-cost component can be ex-
cluded from the final intervention. In addition, the fac-
torial experiment enables examination of mediators of
individual intervention component effects, for a detailed
look at how components operate. It also allows for the
examination of and moderator effects. Regarding moder-
ators, we will conduct exploratory analyses to examine
whether gender, race/ethnicity, substance use patterns,
sexual minority status, and other relevant variables are
moderators of component efficacy. This will inform fu-
ture research aimed at developing adaptive interventions
[145] made of different combinations of components tai-
lored to respond to individual differences (Aim 2).
Explanation for choice of experimental conditions
A complete factorial experiment would have 25 = 32 ex-
perimental conditions. To conserve resources and re-
duce logistical complexity, we have chosen an innovative
25–1fractional factorial design [146] that cuts the num-
ber of experimental conditions in half, to 16. A fractional
factorial design is made up of a strategically selected
subset of the experimental conditions required in a
complete factorial design. These 16 conditions were se-
lected based solely on statistical considerations [36]. We
used PROC FACTEX in SAS to select the design pre-
sented in Fig. 2 [147]. These 16 conditions included in
the fractional factorial design are based on prioritizing
estimation of intervention component main effects and
two-way interactions.
The tradeoff for the economy gained by using a frac-
tional factorial design is that some effects become
entangled or “aliased.” The fundamental principle under-
lying fractional factorial designs is to construct a study
so the effects of primary interest are aliased with effects
not expected to be large or important, typically higher-
order interactions. In our design, each main effect is
aliased with a four-way interaction, and each two-way
interaction is aliased with a three-way interaction.
Because our theoretical model (presented in Fig. 1)
does not specify any sizeable three-way or four-way
interactions, we find this aliasing of effects an accept-
able price to pay for a dramatic reduction in research
implementation costs.
Recruitment
The sampling plan is based on a proven efficient strategy
[33]. PLWH-NECTA, even those out of care, tend to be
networked with other PLWH through HIV and general
social service and substance use settings [7, 148–150],
and through MSM social, drug use, and sexual networks
[151, 152], although a minority are not networked [67].
The sampling plan, a hybrid recruitment strategy, is in-
formed by literature on recruiting hard-to-reach popula-
tions, which calls for extended timeframes, appropriate
resourcing costs, formative research, and community
partnerships [153–155]. The sampling plan has three
main elements: identification of diverse venues where
PLWH-NECTA can be located by professional and peer
experts, targeted sampling by staff/peer recruiter teams,
and peer-to-peer recruitment. Specifically, a Community
Advisory Board (CAB) comprised of local experts and
“successful” members of the target population (former
PLWH-NECTAs) will meet bi-monthly. This CAB will
identify diverse recruitment venues. The hybrid sampling
plan will entail regular targeted sampling events con-
ducted by staff and former PLWH-NECTA from these
organizations. Peer-to-peer recruitment [106] will begin
with a small number of “initial seeds” (N = 5–15) drawn
from the targeted sampling venues and the CAB. Seeds
will be given 3–8 coded recruitment coupons and will
be asked to recruit peers (whom they know by name or
face, are living with HIV, and they believe/suspect are
not engaged in care and/or on ART) for which they will
receive modest compensation ($10/peer) [106]. Peers
will be screened for eligibility and then have the oppor-
tunity to recruit other peers until sample size goals are
met. Sampling will take place in study months 7 to 33
(27 months, 19 participants/month).
Eligibility criteria
Eligibility criteria include: 1) age 18–65 years; 2) African
American/Black or Hispanic race/ethnicity; 3) HIV diag-
nosed for at least 6 months (HIV status confirmed with
medical documentation); 4) has not taken ART in the
past 6 weeks (the period of time assessed by a hair assay,
described below, and a reasonable period of time not on
ART for the present study); 5) sub-optimal engagement
in HIV care (assessed from the medical record, defined
as less than 1 visit in every 4-month period in the past
year [two of them at least 90 days apart], pro-rated for
those diagnosed less than a year ago) or ≥2 missed visits
(without prior cancellation) in the past year [156]; 6)
reside in the New York City metropolitan area; 7) not
planning to leave the New York City metropolitan area
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in next year; 8) not actively psychotic based on screening
instrument [157]; 9) not a participant in the preliminary
pilot HTH study; 10) able to conduct research activities
in English or Spanish; 11) willing to provide hair sample
(if possible), blood samples (to assess CD4, VL), and a
Medical Report Form ([MRF], described below, to assess
health care attendance); 12) willing to participate in a
Core intervention session and be randomly assigned to
1–5 intervention components.
Participant timeline
An easy-access two-step screening procedure has been
designed for efficiency and ease of completion, while
fostering engagement and trust (Fig. 3).
Step 1. First screening interview (by phone) for eligibility
Verbal consent will be obtained and a structured pre-
screening interview will be conducted to preliminarily
screen for eligibility (criteria assessed by self-report). If
preliminarily eligible, next steps to determine eligibility
will be explained.
Step 2. Second screening interview for eligibility (in person)
Written informed consent for the remaining screening
procedures will be obtained, as well as locator informa-
tion. HIV status will be confirmed with medical docu-
mentation provided by the participant, then a hair
sample collected to test whether the participant has used
ART in the past 6 weeks, and a signed Release Form for
Medical Records Office and Health Insurance Portability
and Accountability Act (HIPAA) authorization form for
the MRF will be obtained. Staff will outreach to the
Medical Records office to obtain information on attend-
ance at medical appointments. When MRF and hair
results are received (~2–3 weeks), study eligibility will
be determined.
Screening contingency plans
Those who cannot provide documentation of HIV status
(~25%) will receive pre-test counseling and a point-of-
care HIV test. Further, in past research ~30% of PLWH-
NECTA could not provide a MRF because they did not
have a regular health care provider [34]. In such cases,
self-reported care engagement information will be
accepted. If a hair sample cannot be obtained, a blood
specimen will be obtained and HIV VL ≥ 1000 copies/mL
will serve as a reasonable proxy for ART status (i.e., not
taking ART).
Step 3: The enrollment visit
This visit will entail written informed consent for
remaining study activities, administering the baseline
interview, obtaining a blood specimen for baseline CD4
and VL levels, randomizing the participant to an
experimental condition, and scheduling the Core
intervention session. Random assignment will be
stratified by age (younger PLWH [18–35 years] vs.
older PLWH [36–65 years]). The measures that com-
prise the structured baseline assessment are presented
in Table 1.
Sequence of intervention components
Some of the 16 conditions are intensive but delivery is
feasible, based on our experience with complex interven-
tions. As Fig. 2 shows, the majority of conditions have
3–4 components. Sequences of components will follow
pre-established rules: the Core intervention is delivered
first, MI counseling sessions (where assigned) will come
second, components may be provided simultaneously in
some cases but will be scheduled so they do not conflict,
and pre-adherence preparation will be scheduled to start
after a minimum of 1.5 months of navigation. All partici-
pants receive the core intervention and 3 or 6 months of
First Screen for Eligibility
Verbal informed consent
Brief interview to assess inclusion criteria
Peer recruitment opportunities
Second Screen for Eligibility
Written informed consent
Locator information
Document HIV status, care status (MRF)
Hair or blood sample (VL) – ART status
Enrollment Visit
Written informed consent
Baseline interview
Baseline blood draw (CD4, VL)
Randomization 
HTH2 Intervention (3-8 mos)
Core session
A) MI counseling session (Yes/ No)
B) Pre-adherence preparation (Yes/ No)
C) Peer mentorship (Yes/ No)
D) Support groups (Yes/ No)
E) Navigation (3 mos/ 6 mos)
Follow-Up Period
Structured Assessments @ 4-, 8-, 12-mos post-baseline
Hair sample @ 4-, 8-, 12-mos
Medical Report Forms @ 4- and 12-mos
Blood draw @ 4-mos for VL
Blood draw @ 12-mos for VL and CD4
Qualitative Interview
Fig. 3 Sequence of HTH2-MOST study activities
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navigation, with the intervention periods ranging from
~3.25 to ~8 months. Participants receive modest com-
pensation for intervention activities (e.g., $25 for a ses-
sion, group, or other activity plus funds for two-way
public transportation).
Preventing contamination across experimental conditions
There are two main forms of contamination that could
arise in the present study if a participant learns what other
components (and other forms of intervention/treatment)
a fellow participant is receiving. One potential form of
contamination would be “resentful demoralization;” that
is, participants feeling disappointed or disgruntled by their
treatment in the study relative to other participants, which
could then possibly reduce their motivation to engage in
the study [158]. A second concern would be that a partici-
pant would be triggered to pursue similar types of activ-
ities outside of the study to compensate for what is not
being received in the study. There are two main places
that contamination could occur: in study waiting areas,
and in the focused support group component, when par-
ticipants from different experimental conditions come to-
gether. To prevent contamination from either the “waiting
room” or support group component, participants will be
informed at enrollment that study involvement and com-
pensation varies across participants, in order to manage
expectations. Further, at enrollment we will ask that par-
ticipants not discuss the specifics of study components
with other participants. Then, within the context of the
focus support groups, the facilitator will attend to and dis-
courage discussion of other components by participants in
the groups. We may not be able to eliminate contamin-
ation entirely, but we can takes steps to minimize it.
Blinding of staff members to intervention content
To foster fidelity to the intervention manuals and main-
tain the integrity of each separate component, interven-
tionists will each deliver only one type of component
and will not be trained in the specific content of other
components. For example, interventionists trained to
provide navigation will not be trained in the specifics of
the other four components, and will not deliver any
other component. Further, staff will be blind to partici-
pants’ intervention arm assignments where possible.
Intervention quality assurance
We will establish and maintain treatment fidelity to the 16
conditions and the core elements of each component. A
Research Electronic Data Capture (REDCap) database will
be programmed to reflect the participant’s intervention as-
signments and will prompt interventionist action steps.
REDCap is a secure web application for building and man-
aging online surveys and databases. After each contact, in-
terventionists will complete fidelity checklists. Audiotaped
sessions will be randomly selected and rated for treatment
fidelity by independent raters using the MI Treatment
Integrity (MITI) coding system or a similar coding system.
A clinical supervisor will review recordings of group
sessions. Interventionist fidelity will be reviewed in bi-
monthly individual supervision meetings.
Table 1 Assessment instruments
PROXIMAL MEDIATORS (to assess each intervention component)
Health beliefs (i.e., outcome
expectancies, care/ART
necessity, distrust) and
emotions (i.e., fear)
Outcome expectancies re: care and ART
(9 items each; α = .93) [199]
Care and ART Necessity scale (10 items
each; α = .80) [200]
HIV and ART distrust (10 items; α = .84);
HIV health care provider distrust (11
items; α = .88); General medical distrust
(7 items; α = .72) [201–203]
Care & ART Concerns & Fears subscale
(disclosure, side effects; 13 items;
α = .80) [56, 200]
Adherence behavioral skills Mean % adherence rating from up to 4
one-week trial periods via MEMS caps;
HIV Medication Readiness Scale
(10 items; α = .90) [204]
Peer models and peer norms
regarding HIV care and ART
Peer models (number and quality of
“successful” HIV+ peers in care, on ART;
α = .90) [205]
Subjective peer norms for HIV care and
ART (6 items each; α = .84) [206]
Social support and stigma
associated with care, ART
Social support (α = .88) [207]
Stigma associated with taking or not
taking HIV care and ART (3 items each;
α = .73) [208]
Structural barriers to care/ART HIV-related structural/ practical barriers
to care, ART (α = .72) [136]
DISTAL MEDIATORS Motivation and readiness for care and
ART [209]
Schedule of HIV appointments [210]
ART Prescription [210]
Ancillary treatment [211]
Substance use frequency [212]
Depression [213]
MODERATORS Socio-demographic characteristics (age,
biological sex, sexual minority status,
race/ethnicity)
HIV history and ART history
Substance use [212]
Depression [213]
Anxiety
OTHER DESCRIPTIVE AND
BACKGROUND VARIABLES
Housing status, transgender
gender identity, employment status,
health status; where receives HIV care,
incarceration; sex work history; reasons
not on ART or discontinued ART; ART
side effects (at FU); HIV treatment
knowledge [214]; Methadone
Maintenance/opioid substitution
therapy; satisfaction with HIV care [215]
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Sample size
A total of 512 participants will be enrolled in the experi-
ment. For the primary outcome, HIV viral suppression
at the final follow-up, we used PASS [159] to estimate
the sample size needed for individual main effects of
intervention components corresponding to odds ratios
(OR) of 1.9 in logistic regression, given α = .05. A transi-
tion from viremia to viral suppression has clear clinical
significance for individual patients, and the effect size re-
flects the need to have at least a moderate impact on the
rate of suppression for public health impact. Assuming
participants not receiving or receiving the lowest inten-
sity of each component have a 20% chance of viral
suppression at the final follow-up, a sample size of 404
provides 80% power to detect an OR of 1.9. To account
for attrition of up to 20% of enrolled participants, we
propose a total sample size of 512 participants to ensure
complete data for at least 404. Given the proposed sam-
ple size, when the main effect of an intervention compo-
nent on a continuous measure of a secondary outcome
(e.g., log10 VL) or mediator is estimated in a linear
model or independent-samples t-test, the sample size
provides 80% power to detect a small standardized mean
difference (d = .28). Moderator effects corresponding to
an odds ratio of OR = 1 in one subgroup and OR = 3 in
another can be detected with 76% if subgroups sizes are
roughly equal.
Randomization and data management
A secure, web-based, password-protected database built
on a REDCap platform will be used to manage recruit-
ment, eligibility assessment, randomization to the 16 ex-
perimental conditions, scheduling and tracking, baseline
and follow-up assessments, and delivery of the interven-
tion components (with cues, prompts, pull-down menus,
Likert scales, and open ended responses).
Collection of HIV care patterns using the medical report
form (MRF)
We will obtain a MRF, a type of participant-facilitated
chart review, at screening and the 4- and 12-month
follow-up assessments, by contacting the Medical Re-
cords Office or health care provider where the partici-
pant receives HIV primary care, or asking participants to
have their providers complete a MRF. The MRF will be
completed by the provider and faxed to us in a secure
fax line in a locked office at the New York University
Meyers College of Nursing. The MRF is very brief (so-
licits the number of missed and kept HIV care appoint-
ments), so as to not burden health care providers and
facilities. In the event these data cannot be obtained for
a participant, for example, because the participant does
not have a primary care provider, such data on health
care attendance patterns will be collected by self-report.
Assessing ART adherence levels in hair
Measuring ART exposure via hair is an objective and
innovative biomarker of adherence. Average adherence
to boosted protease inhibitors (PIs) is a better predictor
of virologic suppression than duration or frequency of
missed doses [160]. Further, hair levels of ART have
been found to be stronger predictors of treatment out-
comes than self-reported adherence [103, 161] or single
plasma ART concentrations [161]. Dr. Monica Gandhi, a
study collaborator, has developed methods to analyze
protease inhibitors, Non-Nucleoside Reverse Transcript-
ase Inhibitors (NNRTIs), tenofovir (TFV), and emtricita-
bine (FTC) using liquid chromatography/tandem mass
spectrometry (LC/MS/MS) [103, 162–166]. PIs and
NNRTIs require 20–30 strands of human hair (~1–3 mg
[mg]) and TFV or FTC from 50 to 100 strands of hair
(~5–10 mg). These methods have been validated with
good linearity (R2 > 0.99) and reproducibility (coefficient
of variation [CV] < 15%) for all ART drugs. Moreover,
many of the hair assays developed in our collaborat-
ing laboratory led by Dr. Gandhi have been peer-
reviewed and approved by the NIAID Division of
AIDS Clinical Pharmacology and Quality Assurance
(CPQA) program [167, 168].
Hair collection is noninvasive and does not require
specific skills, sterile equipment, or specialized storage
conditions, and high rates of acceptability and feasibility
of collecting hair samples for hair ART monitoring have
been found in the Women’s Interagency HIV study
(WIHS) [161, 169, 170]. In the present study, 100
strands of hair will be collected and assayed for TFV
concentrations [163] in those on TFV-based regimens (a
commonly-used agent in current regimens) [105]. For
those not on TFV-based regimens, hair samples will be
screened for the anchor antiretroviral (e.g. NNRTI, PI or
integrase inhibitor). At follow-up, participants’ specific
ART regimen will be logged from pill bottles or pre-
scriptions, and hair analyses will be conducted for the
relevant agents.
Follow-up assessment schedule and activities
The follow-up (FU) periods and assessment schedule
(4-, 8, and 12- months post-baseline) are based on
the hypothesized timing and rate of change [171]. The FU
schedule will allow assessment of the initiation and con-
tinuation of and adherence to ART, viral suppression, and
patterns of engagement in care over time. Each FU in-
cludes a brief structured assessment battery (< 60 mins.);
the 4-month FU also includes a blood draw (for VL), hair
sample collection (if taking ART), and completion of a
MRF (for assessment of HIV primary care visits) from par-
ticipants’ HIV care site; the 8-month FU includes hair
sample collection; and the 12-month FU includes a blood
draw (CD4, VL), hair sample collection, and MRF. Specific
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reliable/valid assessment instruments for each mediator
are presented in Table 1, as well as to assess socio-
demographic and background characteristics. Time,
resources, and cost of delivering each intervention compo-
nent will be collected using forms created by the Drug
Abuse Treatment Cost Analysis Program [172]. Partici-
pants receive modest compensation for assessments ($25),
providing hair samples ($10), and blood specimens ($20),
plus funds for two-way public transportation.
Qualitative interviews and data integration
To add context and richness to our understanding of
participants’ experiences with intervention components,
advance understanding of barriers to care/ART, and
inform future research, we will embed qualitative inter-
views into the study. A subset of participants will be
purposively selected for maximum variation for qualita-
tive interviews [173]. We will enroll N = 40 total, or
until saturation on core constructs is reached [174].
Interviews will follow a semi-structured guide with a
“start list” of key questions drawn from the theoretical
model domains, and also allow for exploration of un-
anticipated themes. The use of the start list fosters data
integration across qualitative and quantitative data sets,
because the same core constructs are assessed in each.
Analyses will be conducted by two qualitative re-
searchers using Dedoose (a platform for mixed methods
analysis). Participants receive modest compensation for
the qualitative interview ($25), plus funds for two-way
public transportation.
Statistical methods
Intent-to-treat analysis will be our primary analytic ap-
proach and exploratory analyses will examine complier
average effects of intervention components [175, 176].
Approaches to missing data will include full information
maximum likelihood estimation [177] and multiple im-
putation [173]. In sensitivity analysis, missing data will
be treated as failure to achieve the desired outcome. If
data are missing not at random (MNAR), we will employ
sensitivity analysis, using selection [107] or pattern mix-
ture [178, 179] models.
Aim 1
Identify which of five components contribute meaning-
fully to improvement in the primary outcome, HIV viral
suppression, as well as, absolute HIV viral load; ART
adherence levels; and engagement in HIV care.
The primary outcome for Aim 1 is viral suppression at
the final follow-up point (12-months post-baseline).
Logistic regression will be used to estimate effects of
components on the odds of viral suppression. Experi-
mental factors will be effect coded to estimate main ef-
fects and two-way interactions of all five intervention
components. The coefficient for a main effect term,
multiplied by two and exponentiated, will estimate the
effect of the component on the odds of viral suppres-
sion. Similarly, the coefficient for an interaction term,
multiplied by two and exponentiated, will estimate inter-
action effects between intervention components on the
odds of viral suppression. Similar logistic regression ana-
lyses will estimate effects of components on secondary
outcomes. Linear regression will estimate effects of
components on VL (after log10 transformation) and ART
concentration in hair samples.
Relationships among participants
The sampling and intervention design may create clusters
of participants whose outcomes are not fully independent.
Participants with recruitment relationships may have
more similar outcomes than two randomly selected partic-
ipants. Also, participants receiving an intervention activity
together may have more similar outcomes than randomly
selected participants. Intraclass correlations or median
ORs [180] will be estimated, and the impact of design ef-
fects on inferences will be considered.
Aim 2
Identify mediators and moderators of the efficacy of
each intervention component.
Generalized linear model analysis will determine
impacts of intervention components on mediators.
MacKinnon and Dwyer [181] and MacKinnon [182]
discuss how mediated effects can be calculated when the
outcome or mediator variable is categorical. Probit re-
gression, used to estimate indirect effects, will determine
which mediators are related to viral suppression, after
controlling for intervention components received. Inter-
vention components may not be equally effective for all
participants. The following factors, and others, may
modify the relation between the intervention and out-
comes: age, gender, sexual minority status, and sub-
stance use. The examination of potential moderator
effects will involve forming interaction terms using the
procedures described by Aiken [183] and Jaccard [184]
and estimating simple effects. MOST enables estimation
of moderator effects for each intervention component
and component two-way interactions. Substance use will
be thoroughly characterized in structured assessments
using mainly measures approved by National Institute
on Drug Abuse (NIDA) for the “Seek, Test, Treat, and
Retain” initiative data harmonization effort. Given past
research, we anticipate most participants (~80%) will
have lifetime drug use and approximately half will have
recent substance use. Importantly, we anticipate vari-
ation in a number of salient aspects of substance use
among substance users (e.g., quantity and frequency of
use, consequences of use, duration of use) will allow us
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to consider important intervention effect moderators.
Identified moderators will be used to inform future
development of adaptive interventions [145].
Aim 3
a) Using significance tests and effect size estimates
obtained in Aim 1 analysis, identify components with effi-
cacy, taking interactions into account; b) use modeling to
estimate cost-effectiveness of possible packages composed
of efficacious components; and c) identify the most cost-
effective package.
The selection of the combination of intervention com-
ponents that will make up the new multi-component
“optimized” intervention will proceed as follows [35–37].
First, based on the experimental results, ineffective com-
ponents will be eliminated. Components empirically
demonstrated to be efficacious, and therefore candidates
for inclusion in the optimized intervention, will be
identified using procedures outlined in Collins et al.
[37]. An initially selected component may be deselected
if it interacts with another component in such a way as
to undermine its effect, or a component not initially
selected may be selected if it interacts with another com-
ponent to enhance its effect. Then, drawing from the
remaining components, the set of components/compo-
nent levels that meets the optimization criterion, in this
case cost-effectiveness, will be selected. Starting with ef-
fect sizes and costs of efficacious components, computer
simulation methods will identify intervention packages
that most increase population health for the magnitude
of resources they consume (i.e., on the efficiency frontier
of the cost-effectiveness plane). Enhancing our validated
HIV simulation with new “states” (e.g., disengaged, en-
gaged/not on ART, engaged/on ART but not adherent),
we will consider downstream as well as immediate costs,
and follow guidelines of the Panel on Cost-Effectiveness in
Health in Medicine [185]. Utilities (preference-weighted
quality-of-life measures used in cost-effectiveness ana-
lyses) will vary by CD4 count, and will be based on those
used in the modeling analyses [186–191].
Uncertainty and sensitivity analyses
We will perform a probabilistic sensitivity analysis in
which all inputs are simultaneously varied across their
plausible ranges, and assess the proportion of runs that
an intervention strategy remains on the efficient frontier.
We also will perform a sensitivity analysis by strength of
evidence [192, 193], where we vary an evidence “filter”
that only allows data sources to inform input assump-
tions if they pass through the “filter” and meet the mini-
mum standard of evidence, thereby assessing the lowest
level of evidence filter compatible with a particular inter-
vention strategy remaining on the efficient frontier.
Assumptions
We will make conservative assumptions about duration
of effects, assuming they last only as long as the last
observed follow-up, but will explore more optimistic as-
sumptions in sensitivity analyses. We will base resource
utilization not only on the costs of the intervention
package itself, but also considering changes in attribut-
able downstream costs (e.g. people re-linked to care
might incur lower hospitalization expenses in the long-
term because they maintain higher CD4 counts and are
less likely to get AIDS). Relative trajectories of utilization
pathways (drug costs, outpatient costs including labs
and visits, and inpatient costs) with versus without re-
engagement in care will be estimated based on our
simulation. We will perform analyses from different
perspectives (societal and payer), time horizons (infinite,
20, 10, and 5-year), and discount rates (5%, 3%, and 0%)
but with base case assumptions in accord with estab-
lished guidelines [186, 194–198].
Data monitoring
We will perform reliability checks on measures at an in-
terim analysis point. Construct validity of key measures
will be assessed using measurement models within a
structural equations format (using Mplus).
Fidelity, process ratings, and quality assurance
As noted above, after each intervention session/navigation
contact the interventionist will complete process ratings.
These ratings will be used in regular supervision sessions
to insure fidelity to the intervention manual. Sessions will
be audiorecorded (if participants give their signed
informed consent) and ~10% of the tapes selected at
random will be reviewed for quality assurance and super-
vision purposes by an independent rater who will
complete a standard process rating checklist. They will be
reviewed within approximately a month of their taping to
ensure timely feedback and then destroyed. The facilita-
tors will attend monthly supervision meetings with a se-
nior clinician where quality assurance, clinical issues, and
intervention fidelity issues will be reviewed. The study will
employ a number of procedures to address “drift” from
intervention fidelity including on-going supervision meet-
ings with facilitators and senior staff, regular monitoring
of process ratings, and “booster” training of facilitators
based on the intervention manual provided as needed.
Check on level of missing data and any patterns by item,
data source, or staff person
We propose to use the SPSS Missing Values Analysis
(MVA) program to identify possible non-random pat-
terns of missing data. When items, data sources, or staff
are associated with more than 10% missing data that are
not due to planned interview skip patterns, we will
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determine the causes of missing data and implement
strategies to reduce it (e.g., retraining of staff ).
Harms
The study will make use of a Data Safety and Monitoring
Board (DSMB). Several mechanisms will be put in place
to monitor potentially adverse events that participants
may experience while enrolled in the study, whether they
are related to project participation or not. These
events are classified as either Reportable, Adverse, or
Not Harmful/Expectable, as described below, and will
be reported to the New York University (NYU) and
Pennsylvania State University Institutional Review
Boards (IRBs), DSMB, and the sponsor’s Program Of-
ficer accordingly, as described below. Social harms
will be assessed with a structured instrument at each
FU point, and social harms may be reported during
intervention activities. A Reportable Event is an
unanticipated problem involving risks to participants
or others (“Unanticipated Problem”) and any event or
information that (1) was unforeseen and (2) indicates
that the research procedures caused harm to partici-
pants or others or indicates that participants or
others are at increased risk of harm.
Research ethics approval
The study protocol will be approved by the IRB of the
New York University School of Medicine (the IRB of
record), Pennsylvania State University (Dr. Linda Collins,
Co-Principal Investigator), and Binghamton University
(Dr. Leo Wilton, Co-Investigator).
Consent
Verbal consent will be obtained and a structured pre-
screening interview will be conducted to preliminarily
screen for eligibility (criteria assessed by self-report).
Signed informed consent for the remaining screening
procedures will be obtained. Those found eligible will
provide signed informed consent to enroll in the study.
Participants will provide separate signed consent to have
the qualitative interviews and intervention sessions
audio-recorded. Participants may decline to have their
qualitative interviews or intervention sessions recorded
and still continue with the interviews or sessions. The
voluntary nature of all study activities is emphasized in
the consent forms. The participant will be provided a
copy of the consent form that includes contact informa-
tion for the research team members and the NYU IRB.
Participants can use this contact information to report
adverse events or unanticipated problems.
Confidentiality
All participants will receive a Participant Identification
Number (PID) that will be used for all interviews, forms,
materials, hair samples, blood specimens, transcripts,
and intervention materials. No other information that
would disclose the participant’s identity will be found on
any interview or form. Paper forms will be kept without
serostatus identification in locked cabinets at NYU. Only
the consent form, locator form and a Master Partici-
pant Log File will link the participant’s name to the
identification number. Staff receives training about
confidentiality and the New York State HIV Confi-
dentiality Law. Participants will provide verbal in-
formed consent for the brief screening interview, and
for those found preliminarily eligible, signed informed
consent for remaining study activities (assessments,
blood specimens, hair samples, intervention, peer
recruitment).
Discussion
The goal of elimination of HIV transmission in the United
States will not be achieved without improvements in
engagement along the HIV care continuum. The present
study targets the large population of PLWH in the United
States who are both insufficiently engaged in HIV
primary care and not taking ART, who are mainly
African American/Black and Hispanic. The National
Institutes of Health has emphasized the urgent need
for new research approaches to advance intervention
science, and the proposed project employs a new, po-
tent, and innovative research methodology, the multi-
phase optimization strategy (MOST), a framework for
developing highly efficacious, efficient, scalable, and
cost-effective interventions. The proposed study has
the highest public health significance: it addresses a
vulnerable population of PLWH, including the critic-
ally important subpopulations of MSM and substance
users; will develop an efficient and cost-effective
intervention to increase engagement along the HIV
care continuum for these vulnerable groups; and
addresses two research priorities areas from the Na-
tional Institutes of Health Office of AIDS Research
(NOT-OD-15-137), namely, engaging PLWH in pre-
vention/treatment services, and reducing HIV/AIDS-
related racial/ethnic disparities.
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